Hexagon Capital Partners’s Edwards Lifesciences EW Stock Holding History

Hexagon Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-218	Closed	-$15.8K	–	582
2025 Q1	$15.8K	Sell	218 -242	-53%	-$17.3K	﹤0.01%	826
2024 Q4	$34.1K	Sell	460 -136	-23%	-$9.52K	0.01%	606
2024 Q3	$39.3K	Sell	596 -213	-26%	-$15.5K	0.01%	500
2024 Q2	$74.7K	Buy	809 +106	+15%	+$9.39K	0.02%	351
2024 Q1	$67.2K	Buy	703 +176	+33%	+$14.8K	0.01%	364
2023 Q4	$40.2K	Buy	527 +14	+3%	+$974	0.01%	461
2023 Q3	$35.5K	Hold	513	–	–	0.01%	429
2023 Q2	$48.4K	Hold	513	–	–	0.01%	371
2023 Q1	$42.4K	Hold	513	–	–	0.01%	389
2022 Q4	$38.3K	Hold	513	–	–	0.01%	411
2022 Q3	$42K	Sell	513 -254	-33%	-$24.4K	0.01%	421
2022 Q2	$73K	Hold	767	–	–	0.02%	307
2022 Q1	$90K	Hold	767	–	–	0.02%	291
2021 Q4	$99K	Hold	767	–	–	0.03%	269
2021 Q3	$87K	Hold	767	–	–	0.03%	268
2021 Q2	$79K	Buy	767 +39	+5%	+$3.68K	0.02%	277
2021 Q1	$60K	Sell	728 -3	-0.4%	-$254	0.02%	288
2020 Q4	$66K	Hold	731	–	–	0.02%	241
2020 Q3	$53K	Buy	+731	New	+$57K	0.02%	247

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Hexagon Capital Partners's EW Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 218 shares — an estimated $15.8K sold.

Hexagon Capital Partners first reported a position in EW in Q3 2020 and held it in 19 quarters. The position peaked at $99K in Q4 2021. 1,261 funds tracked by Wall St. Rank hold EW as of Q2 2025.

Hexagon Capital Partners reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 218 Edwards Lifesciences shares in Q2 2025, an estimated $15.8K.
Hexagon Capital Partners first reported a position in Edwards Lifesciences in Q3 2020 and held it in 19 quarters.
Hexagon Capital Partners's Edwards Lifesciences position peaked at $99K in Q4 2021.
1,261 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.